QCLS PharmaCyte Biotech Inc. buys $0 worth of shares
Nov 19, 2025, 5:34 AM
0.00%
What does QCLS do
MyMD Pharmaceuticals, based in Baltimore, develops drug products for aging, autoimmune diseases, and chronic pain, focusing on two platforms: MYMD-1 for inflammation and Supera-CBD for pain and addiction. The company went public in 2008 and employs nine people.
PharmaCyte Biotech Inc. bought 889,865 shares of QCLS on 14 November at $0.00 per share, worth a total of $0. They now own 889,865 QCLS shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.